INFAI, was founded in 1989 by Dr. S. Aygen at the University of Witten-Herdecke.
INFAI is specialized in the transfer of advanced analytical technology in the field of medical diagnostics and the development of innovative pharmaceutical products. The company is a pioneer in the use of stable isotopes in gastroenterology, cardiovascular and inborn metabolic diseases.
In 1997 Helicobacter Test INFAI (HTI) was approved in centralized procedure by EMA first time in all European countries and available for routine diagnosis of Helicobacter pylori infection. In the meantime, HTI registered as medicinal product in more than 40 countries worldwide.
INFAI is a Virtually Integrated Pharmaceutical Company (VIPCO), all legal functions (i.e. Qualified Person, Qualified Person for Pharmacovigilance) are active. There is small Research and Development Department to supervise outsourced tasks. In Marketing own staff oversees the relevant activities.
INFAI’s laboratories in Bochum, Germany and in York, England are equipped with state-of-the-art several IRMS mass spectrometers and 600 MHz NMR spectrometer which is used to investigate metabolic disorders, cardiovascular diseases and a number of other diseases. These facilities are used for internal research and product development, but are also available for collaborative and contract research. In last 20 years, a range of non-invasive, highly efficient breath tests using stable isotopes has been developed. Gastromotal (¹³C octanoic acid gastric emptying test) and Pancreo-Lip (¹³C mixed triglyceride exocrine pancreatic function test) are in preparation for approval by EMA but now available for clinical studies.
INFAI is affiliated with a range of companies throughout Europe. Headquarter is in Cologne, Germany and with subsidiaries in INFAI UK in England, INFAI CH in Switzerland, INFAI France, and INFAI TR in Turkey operates within an international network.